ICS invites all delegates to take part in our product theatres taking place on 8th and 9th September in the exhibition area. Plus our Satellite Symposium session organised and supported by Medtronic, taking place on Thursday 8th September in Hall G1.
Thursday 8th September 2022
AQLANE Medical Product Theatre, 10:50 - 11:00
Rethinking SUI treatment from a women’s perspective with Urolon®, the Bioresorbable Urethral Filler, Alex Lankhorst.
When rethinking SUI treatment from a women’s perspective, the preferred treatment option after PMFT should ideally be minimally-invasive, safe, effective and not placing any permanent materials in the body. Urolon®, a bioresorbable urethral filler, provides this option and closes the gap between conservative and surgical intervention, with a first choice treatment after pelvic floor muscle therapy. Urolon’s principle component are synthetic polycaprolactone (PCL) microspheres suspended in a carboxymethylcellulose (CMC) gel carrier. PCL is a well-known totally bioresorbable soft medical polymer and has been used in numerous CE marked and US FDA approved bioresorbable product applications for several decades and has demonstrated an excellent safety profile. PCL is bioresorbed through hydrolysis and fully excreted through normal metabolic pathways. This session will focus on the clinical data obtained in 2 recently published studies using this product for the treatment of female mild to moderate SUI, demonstrating an excellent safety profile combined with strong efficacy data and Quality of Life improvements up to 2 year follow-up.
Laborie Medical Technologies Product Theatre, 12:45 - 13:15
Laborie your dedicated partner for continence
A glimpse into the world of PrimeSight® Endosheath technology and Optilume® Ureathral Drug Coated Balloon intended for the treatment of strictures in the anterior urethra in adult males.
12:45-13:05: PrimeSight® flexible cystoscopy with single-use Endosheath®, Manfred Lutz
13:05-13:15: Optilume®, Marko Epperlein
Viveca Biomed Product Theatre, 16:10 - 16:20
Contrelle Activgard – the new clinical programme to broaden indications and clinical relevance, including real-world evidence, Andrew Tasker.
A review of Contrelle Activgard clinical results, and with the desire by women to use conservative therapy, demonstration of the increasing relevance in clinical practice. The extensive clinical data is being reinforced with real world feedback focusing on improvements to quality of life. With new pan European availability we’ll introduce the new clinical programme across multiple countries which will extend the relevance to clinical practice and provide new indications, demonstrating reduction in costs in the healthcare system and saving health professional time. We will also introduce our new communication programme to really breakthrough the taboo of female incontinence to help women talk about the issue.
Satellite Symposium, Medtronic, 18:15 - 19:30
Sacral Neuromodulation Therapy with the InterStim™ systems: Remarkable Legacy. Bright Future.
Speakers: Dean Elterman and Charles Knowles
18:15-18:20: Welcome and introduction, Chair
18:20-18:40: Advances in Neuromodulation for OAB, Dean S. Elterman
18:40-19:00: Driven by data – understanding the role of SNM for Faecal Incontinence, Charles H. Knowles
19:00-19:15: Discussion, Q&A
Sacral Neuromodulation therapy is an established treatment option for both Overactive Bladder and Fecal Incontinence as well as for non-obstructive urinary retention. The Medtronic InterStim™ systems have been available for more than 25 years and in this symposium, you will learn how this therapy and its patient selection has evolved over time, what the future holds plus understand the extensive clinical data demonstrating it is an effective treatment option for patients suffering from incontinence.
Friday 9th September 2022
Invivo Bionics Product Theatre, 11:20 - 11:30
A 3 Fr sensor probe for continuous long-term bladder pressure monitoring, Ingelin Clausen.
InVivo Bionics has developed a patented solution for continuous long-term bladder pressure monitoring. The technology is based on more than 10 years of R&D at SINTEF, Norway. One of the world's smallest pressure sensors is the core component in PRESSURO®. It will improve diagnostics for millions of people who struggle with urinary dysfunction. Being able to monitor bladder pressure over time based on natural filling cycles is expected to be a gamechanger in the field of urology. PRESSURO® is expected to enter the market in 2025.
Boston Scientific Product Theatre, 13:10 - 13:55
The Artificial Urinary Sphincter at 50.
We briefly review the 50 years history of the Boston Scientific Artificial Urinary Sphincter After which our experienced faculty will discuss their treatment algorithms and their clinical experience with the AMS-800 in male patients and female patients as well as their experience in replacing these devices (should that prove necessary) and what their experience is with the outcomes in these devices and the level of patient satisfaction. Presenters will also share their own personal history of the AMS-800. At the end of the session there will be time for questions and discussion.
Moderator: Prof. Dr. Laetitia de Kort, University of Utrecht, The Netherlands
13:05-13:15: Introduction, Dr. Laetitia de Kort
13:15-13:30: The AUS in Male Patients, To Be Announced
13:30-13:45: The AUS in Female Patients, Benoit Peyronnet
13:45:13:55: Q & A, Dr. Laetitia de Kort